Which type of acute myeloid leukemia is giritinib (segatan) suitable for?

Gilitinib is an oral selective FLT3tyrosine kinase inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3 gene mutations. FLT3gene mutation is one of the most common driver mutations in AML, which can lead to abnormal proliferation of leukemia cells and increased drug resistance. By targeting the activity of FLT3 kinase, giritinib blocks abnormal signaling pathways, inhibits the proliferation of leukemia cells and induces apoptosis. It has a significant effect on FLT3 mutation-positive AML patients.

Giritinib is suitable for patients with relapsed or refractory AML, especially those with FLT3-ITD or FLT3-TKD mutations. Such patients are prone to relapse after standard chemotherapy, and traditional therapies have limited efficacy. However, giritinib can specifically inhibit the FLT3 mutation signal, improve the remission rate and prolong survival. In clinical trials, giritinib monotherapy showed a high complete response rate and good tolerability, providing a new treatment option for this type of high-risk AML patients.

The use of giritinib needs to be combined with molecular testing results to confirmFLT3 mutation type and mutation load. FLT3-ITDPatients with mutations usually have a poor prognosis, and giritinib can significantly improve their efficacy indicators. In addition, giritinib can also be used as a bridge treatment for patients waiting for bone marrow transplantation to improve the stability of platelet and blood cell counts before transplantation, thereby improving transplantation success rate and overall prognosis.

In clinical application, giritinib needs to be taken orally once a day, and the dose and course of treatment need to be adjusted according to the patient's weight, liver and kidney function, and blood condition. During treatment, blood routine, liver function, electrolytes and QT interval changes need to be closely monitored to prevent adverse events such as fever, diarrhea, abnormal liver function and arrhythmia. At the same time, geritinib is not suitable for AML patients without FLT3 mutations. The molecular target must be clarified before use to ensure the pertinence and safety of the treatment.

Reference materials:https://www.drugs.com/